by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD-GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract INTRODUCTION Real-world data on lecanemab’s efficacy and the longitudinal dynamics of plasma biomarkers are scarce in Chinese patients with Alzheimer’s disease (AD). METHODS In this multicenter cohort study, 181 AD patients received biweekly...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract The Brains for Dementia Research (BDR) project was established to provide high quality, neuropathologically characterized post-mortem brain tissue from a cohort of participants longitudinally assessed for outcomes that are relevant for research in relation to...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Neuro Podcasts
Click here to read the transcript In this episode, I have the opportunity to speak with Dr. Taylor Day (Dr. Tay) to explore the logistics, benefits, and clinical nuances of operating an entirely virtual psychology practice. Dr. Tay shares her transition from academic...
by Clinical Neuropsychologist Online | Monday, October 26, 2026 | Dementia
Abstract Alzheimer’s disease (AD) is the leading cause of dementia worldwide, yet clinical trials remain unrepresentative of those most affected. Ethnic minoritized groups, socioeconomically deprived communities, adults over 75, and populations in low- and...
